Treatment with CFTR modulators and subsequent remission of AA amyloidosis
Clicks: 4
ID: 325238
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
4 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #36 of 125 articles by views in clinical kidney journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 125 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract CFTR modulators have been revolutionary for cystic fibrosis patients but their potential influence on AA amyloidosis has not been investigated. This case report is of a gentleman with cystic fibrosis and nephrotic range proteinuria secondary to AA amyloidosis. At five years following commencement of CFTR modulators, he is in sustained, complete remission with normal urine protein excretion and serum amyloid protein levels within the normal range.
| Reference Key |
openalex_W7203682343
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Rachel McDougall, Christopher Hill |
| Journal | clinical kidney journal |
| Year | 2026 |
| DOI |
10.1093/ckj/sfag266
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.